IKS Health has issued a statement confirming that the introduction of the $100,000 fee for new H-1B visa applications will have no impact on its business operations or financial projections. The company does not rely on H-1B visa holders for its workforce. IKS Health remains committed to its strategy of delivering value through domain expertise and technology-led solutions.
H-1B Visa Fee Change: No Impact
IKS Health, a leading care enablement platform, has addressed recent concerns regarding the newly announced changes to the H-1B visa fee structure. The company confirms that the introduction of the $100,000 fee for new H-1B visa applications does not affect its business operations or financial outlook.
Strategic Focus and Workforce
IKS Health’s business model is built on delivering high-quality solutions through a combination of proprietary technology and a highly skilled workforce primarily based in India, along with a commitment to local hiring in the United States. The company emphasizes that H-1B visas are not essential for its core business operations or client service delivery.
Continued Commitment
IKS Health assures its stakeholders that these regulatory changes will not impede its ability to serve clients, maintain operational continuity, or achieve its long-term growth objectives. The company remains dedicated to its strategy of providing value through deep domain expertise, technology-led solutions, and a robust global delivery framework. IKS Health will continue to monitor global regulatory developments and keep its stakeholders informed.
About IKS Health
IKS Health focuses on streamlining healthcare operations to allow clinicians to concentrate on delivering exceptional care. By integrating practical technology and experienced professionals, IKS Health enables financially sustainable healthcare enterprises. Their Care Enablement Platform offers data-driven value and expertise across the care process. Founded in 2006, IKS Health supports large health systems across the United States.
Source: BSE
